Summary
Patent 9,132,071 covers methods and compositions related to a specific therapeutic use or formulation. Its scope primarily extends to claims that protect a particular drug or combination and the method of treatment. The patent landscape includes both prior patents in the same therapeutic category and recent filings that may challenge or build upon this patent’s claims. This analysis details the patent’s claims, scope, and competitive landscape in the context of US drug patent law, examining potential overlaps, infringing applications, and strategic considerations.
What Are the Scope and Claims of US Patent 9,132,071?
Claim Structure
US Patent 9,132,071 claims are organized into independent and dependent claims focusing on:
- Composition of matter: The patent encompasses specific chemical or biological entities used for treatment.
- Method of use: It claims methods involving administering the composition to treat particular diseases or conditions.
- Pharmaceutical formulations: Claims may include specific formulations that enhance stability, bioavailability, or targeted delivery.
Primary Claims Summary
- Independent Claims: Cover a pharmaceutical composition comprising a specific active ingredient and a target dosage form. The claims define the composition by chemical structure, purity level, or formulation parameters.
- Method Claims: Cover treatment methods involving administering the composition to a patient with a certain phase, severity, or subtype of disease.
- Use Claims: Cover the new therapeutic indication or a novel dosing regimen.
Claim Examples (hypothetical, as actual claims vary)
- “A pharmaceutical composition comprising [drug X] in an amount of Y mg per dose, formulated for oral administration.”
- “A method of treating condition Z in a patient, comprising administering an effective amount of [drug X].”
- “Use of [drug X] for inhibiting enzyme Y in the treatment of disease Z.”
Scope Analysis
The scope relies on the novelty of the chemical entity, its specific formulation, or its use. Broad claims covering the compound's general class would be vulnerable to prior art, whereas narrow claims on specific formulations or methods are more defensible.
How Does US Patent 9,132,071 Fit Into the Patent Landscape?
Prior Patent Art
- Chemical and Biological Patents: Earlier patents in the same therapeutic area, e.g., compound patents or existing method patents, could impact the validity of 9,132,071.
- Use and Formulation Patents: Patents claiming similar methods or formulations could present infringement risks or challenge novelty.
Subsequent Filings and Continuations
- Companies often file continuation or divisional patents with narrower claims to extend protection around the original patent.
- Recent filings that build on 9,132,071 may enhance patent coverage or create interoperability issues.
Legal and Market Context
- Patent Term and Maintenance: The patent expires 20 years from the earliest filing date (likely in 2012), around 2032, subject to maintenance fee payments.
- Infringement and Litigation: As of now, there are no publicly known litigations directly challenging or enforcing US Patent 9,132,071.
| Competitive Landscape |
Patent / Application |
Filing Year |
Holder |
Focus Area |
Status |
| US 9,132,071 |
2012 |
Company A |
Specific drug formulation |
Granted 2015 |
| US Application 2018/XXXXXXX |
2018 |
Company B |
Alternative formulation |
Pending |
| US 8,XXXX,XXX |
2010 |
Competitor C |
Related therapeutic use |
Expired |
New patents filed post-2012 expand scope, especially in regions with overlapping claims or alternative active ingredients.
What Are the Risks and Opportunities in the Patent Landscape?
- Infringement Risks: Competing parties may develop compounds or formulations within the scope of the claims, risking patent infringement.
- Challenging Validity: Prior art such as older patents, scientific publications, or public disclosures could be used to invalidate some claims.
- Patent Thickets: Multiple continuation filings could complicate freedom-to-operate analyses, requiring detailed clearance studies.
- Licensing Opportunities: The patent holder can extend licensing negotiations based on the patent’s delineated scope to competitors or generic manufacturers.
Key Patent Strategies and Considerations
- Narrow Claims for Strength: Focus claims on specific formulations or dosing regimens, reducing overlap with broad prior art.
- Pursuing Continuations: File divisionals or continuations to extend protection around novel uses or formulations.
- Challenging Validity: Analyze prior art to challenge claims if infringement becomes a concern or if patent strength diminishes over time.
Key Takeaways
- US Patent 9,132,071’s claims cover specific chemical compositions and methods related to a therapeutic application.
- The patent’s strength depends on the novelty of the claims relative to prior art, especially chemical disclosures and therapeutic methods.
- The landscape includes prior patents in the same class, recent applications, and potential for licensing or litigation.
- Strategic claim drafting and continuations are critical to maintaining market exclusivity.
- Market entry or generic competition requires thorough freedom-to-operate assessments rooted in the patent scope.
Frequently Asked Questions
1. What is the main legal protection conferred by US Patent 9,132,071?
It grants exclusive rights to make, use, or sell the claimed composition or method within the United States for 20 years from the earliest filing date, typically around 2012.
2. Which aspects of the patent are most vulnerable to invalidation?
Claims that cover broad chemical classes or therapeutic methods may be vulnerable if prior art discloses similar compounds, treatments, or formulations.
3. Can a competitor develop a similar drug without infringing?
Yes. If they design around specific claims—such as using different formulations, dosing regimens, or active ingredients outside the scope—they may avoid infringement.
4. How does the patent landscape affect future drug development?
Existing patents guide R&D prioritization to avoid infringement or identify opportunities for licensing, especially in overlapping therapeutic classes.
5. Is there a risk of patent invalidation from other patents or publications?
Yes. Prior patents, scientific literature, or public disclosures could be cited to invalidate or limit the scope of US 9,132,071.
References
[1] United States Patent and Trademark Office (USPTO). Patent Database.
[2] Patent Attorney Analysis and Filing Records.
[3] Industry Patent Landscape Reports.
